including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.

The worsening Avian Flu crisis adds optionality to Moderna shares. Moderna became a household name during the pandemic, but more recently COVID booster vaccination rates are slowing and the ...

A protein-based booster vaccine made by Novavax, which works differently to the Pfizer and Moderna jabs, is also available. Moderna is hoping to launch a combined flu and Covid vaccine in 2025 or ...

For the fourth time in five months, the Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near ...

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

There have been 67 confirmed human bird flu cases in the U.S. since April 2024. Moderna has been awarded approximately $590 million from the federal government to help speed up the development of ...

Despite this funding boost, Moderna has indicated that it does not expect this to contribute to its revenue in the near term, as the associated expenses are anticipated to offset the financial inflow.

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

Jan 17 (Reuters) - The U.S. government has awarded Moderna (MRNA.O), opens new tab $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle ...

Moderna (NASDAQ:MRNA) was among the notable gainers on Wednesday after Oracle (NYSE:ORCL) Chairman Larry Ellison highlighted the AI's potential in the development of messenger RNA-based cancer ...